Haploinsufficiency of target of rapamycin attenuates cardiomyopathies in adult zebrafish

Yonghe Ding, Xiaojing Sun, Wei Huang, Tiffany Hoage, Margaret May Redfield, Sudhir Kushwaha, Sridhar Sivasubbu, Xueying Lin, Stephen C Ekker, Xiaolei H Xu

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

RATIONALE: Although a cardioprotective function of target of rapamycin (TOR) signaling inhibition has been suggested by pharmacological studies using rapamycin, genetic evidences are still lacking. We explored adult zebrafish as a novel vertebrate model for dissecting signaling pathways in cardiomyopathy. OBJECTIVE: We generated the second adult zebrafish cardiomyopathy model induced by doxorubicin. By genetically analyzing both the doxorubicin and our previous established anemia-induced cardiomyopathy models, we decipher the functions of TOR signaling in cardiomyopathies of different etiology. METHODS AND RESULTS: Along the progression of both cardiomyopathy models, we detected dynamic TOR activity at different stages of pathogenesis as well as distinct effects of TOR signaling inhibition. Nevertheless, cardiac enlargement in both models can be effectively attenuated by inhibition of TOR signaling through short-term rapamycin treatment. To assess the long-term effects of TOR reduction, we used a zebrafish target of rapamycin (ztor) mutant identified from an insertional mutagenesis screen. We show that TOR haploinsufficiency in the ztor heterozygous fish improved cardiac function, prevented pathological remodeling events, and ultimately reduced mortality in both adult fish models of cardiomyopathy. Mechanistically, these cardioprotective effects are conveyed by the antihypertrophy, antiapoptosis, and proautophagy function of TOR signaling inhibition. CONCLUSIONS: Our results prove adult zebrafish as a conserved novel vertebrate model for human cardiomyopathies. Moreover, we provide the first genetic evidence to demonstrate a long-term cardioprotective effect of TOR signaling inhibition on at least 2 cardiomyopathies of distinct etiology, despite dynamic TOR activities during their pathogenesis.

Original languageEnglish (US)
Pages (from-to)658-669
Number of pages12
JournalCirculation Research
Volume109
Issue number6
DOIs
StatePublished - Sep 2 2011

Fingerprint

Haploinsufficiency
Zebrafish
Sirolimus
Cardiomyopathies
Doxorubicin
Vertebrates
Fishes
Insertional Mutagenesis

Keywords

  • anemia
  • cardiomyopathy
  • cardiotoxicity
  • doxorubicin
  • target of rapamycin
  • zebrafish

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Haploinsufficiency of target of rapamycin attenuates cardiomyopathies in adult zebrafish. / Ding, Yonghe; Sun, Xiaojing; Huang, Wei; Hoage, Tiffany; Redfield, Margaret May; Kushwaha, Sudhir; Sivasubbu, Sridhar; Lin, Xueying; Ekker, Stephen C; Xu, Xiaolei H.

In: Circulation Research, Vol. 109, No. 6, 02.09.2011, p. 658-669.

Research output: Contribution to journalArticle

Ding, Yonghe ; Sun, Xiaojing ; Huang, Wei ; Hoage, Tiffany ; Redfield, Margaret May ; Kushwaha, Sudhir ; Sivasubbu, Sridhar ; Lin, Xueying ; Ekker, Stephen C ; Xu, Xiaolei H. / Haploinsufficiency of target of rapamycin attenuates cardiomyopathies in adult zebrafish. In: Circulation Research. 2011 ; Vol. 109, No. 6. pp. 658-669.
@article{3d7e3bc122094e418b5bb31daa4b3176,
title = "Haploinsufficiency of target of rapamycin attenuates cardiomyopathies in adult zebrafish",
abstract = "RATIONALE: Although a cardioprotective function of target of rapamycin (TOR) signaling inhibition has been suggested by pharmacological studies using rapamycin, genetic evidences are still lacking. We explored adult zebrafish as a novel vertebrate model for dissecting signaling pathways in cardiomyopathy. OBJECTIVE: We generated the second adult zebrafish cardiomyopathy model induced by doxorubicin. By genetically analyzing both the doxorubicin and our previous established anemia-induced cardiomyopathy models, we decipher the functions of TOR signaling in cardiomyopathies of different etiology. METHODS AND RESULTS: Along the progression of both cardiomyopathy models, we detected dynamic TOR activity at different stages of pathogenesis as well as distinct effects of TOR signaling inhibition. Nevertheless, cardiac enlargement in both models can be effectively attenuated by inhibition of TOR signaling through short-term rapamycin treatment. To assess the long-term effects of TOR reduction, we used a zebrafish target of rapamycin (ztor) mutant identified from an insertional mutagenesis screen. We show that TOR haploinsufficiency in the ztor heterozygous fish improved cardiac function, prevented pathological remodeling events, and ultimately reduced mortality in both adult fish models of cardiomyopathy. Mechanistically, these cardioprotective effects are conveyed by the antihypertrophy, antiapoptosis, and proautophagy function of TOR signaling inhibition. CONCLUSIONS: Our results prove adult zebrafish as a conserved novel vertebrate model for human cardiomyopathies. Moreover, we provide the first genetic evidence to demonstrate a long-term cardioprotective effect of TOR signaling inhibition on at least 2 cardiomyopathies of distinct etiology, despite dynamic TOR activities during their pathogenesis.",
keywords = "anemia, cardiomyopathy, cardiotoxicity, doxorubicin, target of rapamycin, zebrafish",
author = "Yonghe Ding and Xiaojing Sun and Wei Huang and Tiffany Hoage and Redfield, {Margaret May} and Sudhir Kushwaha and Sridhar Sivasubbu and Xueying Lin and Ekker, {Stephen C} and Xu, {Xiaolei H}",
year = "2011",
month = "9",
day = "2",
doi = "10.1161/CIRCRESAHA.111.248260",
language = "English (US)",
volume = "109",
pages = "658--669",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Haploinsufficiency of target of rapamycin attenuates cardiomyopathies in adult zebrafish

AU - Ding, Yonghe

AU - Sun, Xiaojing

AU - Huang, Wei

AU - Hoage, Tiffany

AU - Redfield, Margaret May

AU - Kushwaha, Sudhir

AU - Sivasubbu, Sridhar

AU - Lin, Xueying

AU - Ekker, Stephen C

AU - Xu, Xiaolei H

PY - 2011/9/2

Y1 - 2011/9/2

N2 - RATIONALE: Although a cardioprotective function of target of rapamycin (TOR) signaling inhibition has been suggested by pharmacological studies using rapamycin, genetic evidences are still lacking. We explored adult zebrafish as a novel vertebrate model for dissecting signaling pathways in cardiomyopathy. OBJECTIVE: We generated the second adult zebrafish cardiomyopathy model induced by doxorubicin. By genetically analyzing both the doxorubicin and our previous established anemia-induced cardiomyopathy models, we decipher the functions of TOR signaling in cardiomyopathies of different etiology. METHODS AND RESULTS: Along the progression of both cardiomyopathy models, we detected dynamic TOR activity at different stages of pathogenesis as well as distinct effects of TOR signaling inhibition. Nevertheless, cardiac enlargement in both models can be effectively attenuated by inhibition of TOR signaling through short-term rapamycin treatment. To assess the long-term effects of TOR reduction, we used a zebrafish target of rapamycin (ztor) mutant identified from an insertional mutagenesis screen. We show that TOR haploinsufficiency in the ztor heterozygous fish improved cardiac function, prevented pathological remodeling events, and ultimately reduced mortality in both adult fish models of cardiomyopathy. Mechanistically, these cardioprotective effects are conveyed by the antihypertrophy, antiapoptosis, and proautophagy function of TOR signaling inhibition. CONCLUSIONS: Our results prove adult zebrafish as a conserved novel vertebrate model for human cardiomyopathies. Moreover, we provide the first genetic evidence to demonstrate a long-term cardioprotective effect of TOR signaling inhibition on at least 2 cardiomyopathies of distinct etiology, despite dynamic TOR activities during their pathogenesis.

AB - RATIONALE: Although a cardioprotective function of target of rapamycin (TOR) signaling inhibition has been suggested by pharmacological studies using rapamycin, genetic evidences are still lacking. We explored adult zebrafish as a novel vertebrate model for dissecting signaling pathways in cardiomyopathy. OBJECTIVE: We generated the second adult zebrafish cardiomyopathy model induced by doxorubicin. By genetically analyzing both the doxorubicin and our previous established anemia-induced cardiomyopathy models, we decipher the functions of TOR signaling in cardiomyopathies of different etiology. METHODS AND RESULTS: Along the progression of both cardiomyopathy models, we detected dynamic TOR activity at different stages of pathogenesis as well as distinct effects of TOR signaling inhibition. Nevertheless, cardiac enlargement in both models can be effectively attenuated by inhibition of TOR signaling through short-term rapamycin treatment. To assess the long-term effects of TOR reduction, we used a zebrafish target of rapamycin (ztor) mutant identified from an insertional mutagenesis screen. We show that TOR haploinsufficiency in the ztor heterozygous fish improved cardiac function, prevented pathological remodeling events, and ultimately reduced mortality in both adult fish models of cardiomyopathy. Mechanistically, these cardioprotective effects are conveyed by the antihypertrophy, antiapoptosis, and proautophagy function of TOR signaling inhibition. CONCLUSIONS: Our results prove adult zebrafish as a conserved novel vertebrate model for human cardiomyopathies. Moreover, we provide the first genetic evidence to demonstrate a long-term cardioprotective effect of TOR signaling inhibition on at least 2 cardiomyopathies of distinct etiology, despite dynamic TOR activities during their pathogenesis.

KW - anemia

KW - cardiomyopathy

KW - cardiotoxicity

KW - doxorubicin

KW - target of rapamycin

KW - zebrafish

UR - http://www.scopus.com/inward/record.url?scp=80052581224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052581224&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.111.248260

DO - 10.1161/CIRCRESAHA.111.248260

M3 - Article

C2 - 21757652

AN - SCOPUS:80052581224

VL - 109

SP - 658

EP - 669

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 6

ER -